[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"substance-use-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:substance-use-disorder":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,55,86,117,147,182,208,233,260,284,312,338],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053999","olfactory-function-and-model-based-behavior-in-people-living-with-hiv-and-sud-100053999",false,"NCT07637669","Olfactory Function and Model-Based Behavior in People Living With HIV and SUD","Olfactory Function and Model-based Behavior in People Living With HIV and SUD","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\nFor all participants:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Aged 18-65 years old. Justification: prevalence of olfactory impairments increases with age; after age 53, the prevalence is 24.5 percent, increasing to 62.5 percent in people ages 80-97.\n* Agreement to adhere to Lifestyle Considerations throughout study duration.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nFor participants in the HIV+ and SUD+ and HIV+ and SUD- groups:\n\n-HIV positive.\n\nFor participants in the HIV+ and SUD+ and HIV- \\& SUD+ groups:\n\n-Substance Use Disorder (SUD) other than Alcohol Use Disorder (AUD) or Tobacco Use Disorder (TUD).\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nFor all participants:\n\n* History of neurological illnesses or neurosurgery including but not limited to cerebrovascular accident, Parkinson disease, Alzheimer disease, Huntington disease, central nervous system (CNS) tumor, significant head trauma with sequelae, multiple sclerosis or other demyelinating diseases, epilepsy, movement disorders. The MAI will also retain discretion to exclude based on a history of a neurological illness or trauma that may compromise data integrity.\n* History of current (past 12 months) uncontrolled major DSM-5 psychiatric disorder including major affective disorder, obsessive-compulsive disorder, schizophrenia, or posttraumatic stress disorder, excluding SUD.\n* Candidates who recently (12 hours prior to a study visit) used medications and\u002For substances that are psychoactive or otherwise affect alertness will have to pass a clinical assessment for intoxication on the day of the study visit. Based on participant preferences and MAI\u002FPI judgment, participants who fail the clinical assessment for intoxication will either be withdrawn or rescheduled.\n* History of clinically significant anaphylaxis, e.g., due to severe asthma or food and nonfood allergies (e.g., latex, detergents, soap, etc.). The MAI will retain discretion to exclude a participant based on this criterion.\n* Uncorrected impairments in visual acuity.\n* Non-English speaking. Justification: The data integrity of some of the behavioral tasks used in this study would be compromised as they have only been validated in English.\n* Pregnancy.\n* Any other condition that in the judgment of the investigators is incompatible with participation.\n\nFor participants in the HIV+ and SUD- and HIV- and SUD- groups:\n\n* History of current (past 12 months) SUD, excluding tobacco use disorder.\n* Pattern of alcohol and drug use in the past 12 months that is indicative of harmful use, loss of control over use, or physical dependence.\n* Daily alcohol or drug use (excluding caffeine and nicotine) for at least 4 continuous weeks in the past 12 months.\n\nFor participants in the HIV- and SU+ and HIV- and SUD- groups:\n\n-HIV positive.\n\nFor the Optional MRI Segment:\n\n-Unable to undergo MRI scanning due to certain metallic or magnetic devices or implants in the body, or claustrophobia.","ALL","18 Years","65 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","Background:\n\nHuman immunodeficiency virus (HIV) infection can affect areas of the brain that control thinking ability. These same areas of the brain also control the sense of smell. HIV infection is common in people with substance use disorder (SUD). SUD also affects thinking ability. Researchers want to learn more about the connection between the sense of smell and decision-making ability in people with HIV, SUD, or both.\n\nObjective:\n\nTo test the sense of smell in people with HIV and\u002For SUD and how they make choices based on odors.\n\nEligibility:\n\nPeople aged 18 to 65 years with any of these: (1) HIV, (2) SUD, (3) both HIV and SUD, or (4) neither SUD nor HIV.\n\nDesign:\n\nParticipants will have 2 visits. Each visit will last 3 to 5 hours.\n\nIn visit 1, participants will have a blood draw and a saliva swab. They will answer questions about their health, sleep habits, food intake, and substance use. They will have smell tests:\n\nThey will smell scented sticks and answer questions about them. They will be blindfolded for some tests.\n\nThey will perform tasks on a computer. They will look at pictures and smell pleasant food odors, such as chocolate cake or pizza. Smells will be delivered using a nasal mask. Their sniffing and breathing will be measured. They may also be exposed to odor-free air. They will eat food that corresponds to one of the food odors they smelled.\n\nIn visit 2, participants will do a saliva swab and a different computer task that involves odors. They will also have tests of their attention and memory. Participants may opt to have an imaging scan of the brain.",[25,26],"HIV","Substance Use Disorder",[25,26,28,29],"Olfaction","Decision Making","NOT_YET_RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":21},"2026-07-16",{"date":38,"type":21},"2031-06-27",{"name":40,"class":41},"National Institute on Drug Abuse (NIDA)","NIH",1,{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":45,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":46,"keywords":47,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":54,"locationsCount":42},"100641768",{"count":20,"type":21},[25,26],[25,26,28,29],"2026-07-01",{"date":50,"type":34},"2026-07-02",{"date":52,"type":21},"2026-07-07",{"date":38,"type":21},{"name":40,"class":41},{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":16,"minAge":17,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":42},"100480663","defining-neurobiological-links-between-substance-use-and-mental-illness-100480663","NCT05538910","Defining Neurobiological Links Between Substance Use and Mental Illness","* INCLUSION CRITERIA:\n\nTo be eligible for this study, an individual must meet all the following criteria assessed under the currently approved NIDA IRP screening protocol for the evaluation of potential research subjects (here referred to as the NIDA screening protocol). This is a protocol led by the Office of the Clinical Director (OCD) at the National Institute on Drug Abuse Intramural Research Program (NIDA IRP) to assess potential research participants eligibility for entering clinical protocols at the NIDA\u002FIRP. Additional details can be found in the NIDA screening protocol documents. As routinely done at the NIDA IRP, the screening procedures and data collected under the NIDA\n\nscreening protocol will capture information above and beyond what is necessary to determine eligibility for this protocol but allows the Investigators to assess the eligibility criteria for this protocol.\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\nAll Participants:\n\n1. Able and willing to provide written informed consent.\n2. Both sexes and all ethnic origins, age between 18 and 60 at the time of consent. Justification: Many neural processes change with age, and these changes could introduce unwanted variability in both behavioral and MRI signals.\n3. Be generally healthy\n4. Absence of pregnancy and breastfeeding. Justification: study procedures and drugs used in the current protocol may complicate pregnancy or be transferred to nursing children. Assessment tool(s): Urine and\u002For serum pregnancy tests, and clinical interview. Urine pregnancy tests will also be conducted at the beginning of each imaging visit.\n5. Have a Breath Alcohol Value of 0 on all study visit days involving scanning. Participant may be rescheduled if this value is greater than 0.\n\nMDD Subjects:\n\n1. Meet DSM-5 diagnostic criteria for current MDD at screening Clinical judgement will be used to interpret criteria.\n2. Have a baseline (Hamilton Depression) HAM-D score indicative of current depression as evaluated by clinical staff.\n3. Current stable serotonin modulating drug (e.g. SSRI\u002FSNRI\u002Fserotonin modulator) treatment is allowed (no changes in the last 2 months). Specific medications will be evaluated by the MAI\n\nRemitted MDD Subjects:\n\n1. Meet DSM-5 diagnostic criteria for remitted MDD (full remission or partial remission or past depression) Clinical judgement will be used to interpret criteria.\n2. HAM-D score indicating no clinically relevant depression as evaluated by clinical staff.\n3. Current stable serotonin modulating drug (e.g. SSRI\u002FSNRI\u002Fserotonin modulator) treatment is allowed (no changes in the last 2 months). Specific medications will be evaluated by the MAI.\n\nControl Subjects (without MDD):\n\n1. In addition to the absence of medical, neurological, and psychiatric illness listed above, control participants must not have current\u002Flifetime MDD. Clinical judgement will be used to interpret criteria.\n2. HAM-D score indicating no clinically-relevant depression as evaluated by clinical staff.\n\nDaily Nicotine Users (Study Arm 2):\n\n1. Uses nicotine daily for at least six months\n2. Positive urine screen for cotinine\n\nEXCLUSION CRITERIA (STUDY ARM 1):\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Subjects with suicidal ideation where outpatient treatment is determined unsafe.\n2. Lifetime history or current diagnosis of any of the following psychiatric illnesses: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features. The MAI and\u002For PI\u002FLI will reserve the right to exclude based psychiatric history not explicitly described in this criterion\n\n   a. Within the control group, Current\u002Flifetime MDD will be exclusionary for controls. Those currently using antidepressants to treat anxiety disorders typically co-morbid with MDD such as general anxiety disorder and panic disorder will be excluded. The MAI will reserve the right to exclude on the basis of psychiatric history not explicitly described in this criterion.\n3. Are cognitively impaired or have a learning disability severe enough to have required intervention throughout most or all of K-12 education. The MAI will reserve the right to evaluate if a participant s history of educational placement is likely to represent a learning disability that could significantly impact the data gathered in this study based on the severity and type of learning disability. Justification: Cognitive impairment and learning disabilities may be associated with altered brain functioning in regions recruited during laboratory task performance.\n4. Heavy caffeine users (consume greater than 500 mg on a regular or daily basis. This is approximately five 8 fl oz cups of coffee). Participants will be asked to not deviate from their typical caffeine use on all scanning days.\n5. May not have regularly used any nicotine product in the past year; must never have been daily nicotine users for more than 1 month.\n6. Must have an expired carbon monoxide level of less than or equal to 5 ppm and cotinine levels consistent with a non-smoker. Depending on the commercially available test used, a level equivalent to a non-smoker status will be used, ideally indicative of a urine cotinine level of around 10 ng\u002Fml. However, given the known limitations of rapid tests to return specific quantifications of cotinine levels, if the present test is unable to quantify cotinine at this level, the lowest level of detection will be used as a cut off and MAI \u002F PI discretion may be used to determine whether this cut off coupled with participant history and environmental factors indicates personal nicotine use versus secondhand smoke environment.\n7. History of moderate or severe substance use disorder in the past 6 months (other than caffeine)\n8. Current pharmacological treatment for opioid use disorder (i.e., use of methadone)\n9. Current use of illegal drugs other than marijuana as measured by urine drug screen Marijuana will not be allowed in the 24 hours prior to scanning based on self-report. Study day can be rescheduled to accommodate.\n10. Participants may not use anticholinergic drugs (i.e., scopolamine), dopamine enhancing drugs (i.e. methylphenidate), or other medications that may impact MRI measures (i.e. benzodiazepines) prior to any scanning visit within a timeframe that is likely to directly\n\n    impact the study questions. MAI discretion regarding timeframe of allowed use will be based on half-life, pharmacology of the drug in question, and pattern of use by the participant. Scanning visit timing can be adjusted to accommodate.\n11. May not use drugs that directly enhance dopamine (i.e., methylphenidate) in the week prior to any scanning visit. Scanning visit timing can be adjusted to accommodate.\n12. Any past or present significant cardiovascular, cerebrovascular, or respiratory conditions, including arrhythmias, acute coronary syndrome, ischemic heart disease, or, uncontrolled hypertension\n13. Body mass index (BMI) lower than 18.5 kg\u002Fm\\^2\n14. Contraindications to MRI as determined by MRI Safety Screening form and mock scanner trial (when available).\n15. Abnormal structural MRI, significant head trauma, current neurological illness including but not limited to frequent migraines, multiple sclerosis, movement disorder\n16. Lifetime history of significant seizure disorder\n17. Any other serious or unstable medical illness as defined by self-report, the evaluation of vital signs or other observation that in the view of the investigators would compromise the safety of an individual during participation\n\n    All data collected will be evaluated by members of the study team to decide if there is an existing medical illness that would compromise participation in this research\n18. Subjects that cannot speak English. Justification: To include non-English speakers, we would have to translate the consent and other study documents and hire and train bilingual staff, which would require resources that we do not have and could not justify, given the small sample size for each experiment. Additionally, the data integrity of some of the cognitive tasks and standardized questionnaires used in this study would be compromised as they have only been validated in English. Most importantly, ongoing communication regarding safety procedures is necessary when participants are undergoing MRI procedures. The inability to effectively communicate MRI safety procedures in a language other than English could compromise the safety of non-English speaking participants\n\nExclusion Criteria (Study Arm 2)\n\n1. Subjects with active suicidal ideation where outpatient treatment is determined unsafe.\n2. Current psychiatric symptoms in which the ability to adhere to study protocol is determined to be impaired by clinical staff\u002FMAI (e.g., difficulty understanding or answering questions, difficulty remaining still in the fMRI scanner)\n3. Are cognitively impaired or have a learning disability severe enough to have required intervention throughout most or all of K-12 education. The MAI will reserve the right to evaluate if a participant s history of educational placement is likely to represent a learning disability that could significantly impact the data gathered in this study based on the severity and type of learning disability.\n\n   Justification: Cognitive impairment and learning disabilities may be associated with altered brain functioning in regions recruited\n\n   during laboratory task performance.\n4. Heavy caffeine users (consume greater than 500 mg on a regular or daily basis. This is approximately five 8 fl oz cups of coffee). Participants will be asked to not deviate from their typical caffeine use on all scanning days.\n5. Active severe substance use disorder in the past 6 months (other than caffeine and nicotine)\n6. Contraindications to MRI as determined by MRI Safety Screening form and mock scanner trial (when available).\n7. Abnormal structural MRI, significant head trauma, current neurological illness likely to impact fMRI signal or ability to comply with study requirements (e.g., staying still in scanner)\n8. Any serious or unstable medical illness as defined by self-report, the evaluation of vital signs or other observation that in the view of the investigators, would compromise the safety of an individual during participation. All data collected will be evaluated by members of the study team to decide if there is an existing medical illness that would compromise participation in this research\n9. Subjects that cannot speak English. Justification: To include non-English speakers, we would have to translate the consent and other study documents and hire and train bilingual staff, which would require resources that we do not have and could not justify, given the small sample size for each experiment. Additionally, the data integrity of some of the cognitive tasks and standardized questionnaires used in this study would be compromised as they have only been validated in English. Most importantly, ongoing communication regarding safety procedures is necessary when participants are undergoing MRI procedures. The inability to effectively communicate MRI safety procedures in a language other than English could compromise the safety of non-English speaking participants",true,"60 Years",{"count":64,"type":21},620,"INTERVENTIONAL",[67],"NA","Background:\n\nNicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting compared with smokers without MDD. More research is needed on how nicotine affects brain function in those with MDD.\n\nObjective:\n\nTo understand how nicotine affects symptoms of depression and related brain function.\n\nEligibility:\n\nPeople aged 18 to 60 years, at the time of consent, with and without MDD who do not smoke cigarettes or use other nicotine products.\n\nDesign:\n\nParticipants will have 2 or 3 study visits over 1 year.\n\nParticipants will have 2 MRI scans no less than 4 days apart. Each scan visit will last 5 to 7 hours. At each scan, they will have urine and breath tests to screen for recent use of alcohol, nicotine, and illegal drugs.\n\nBefore each scan, they will take 1 of 2 medications: nicotine or placebo. Participants will receive each medication once. They will not know which medication they are receiving at each scan.\n\nFor each MRI scan, they will lie on a table that slides into a cylinder. Sometimes they will be asked to lie still. Sometimes they will complete tasks on a computer. Tasks may include identifying colors or playing games to win money. Each scan will take about 2 hours.\n\nParticipants will answer questions about their thoughts, feelings, and behaviors before and after each scan.\n\nThey will have a blood test after each scan.",[70,26,71],"Major Depressive Disorder","Normal Physiology",[73,74,75,76],"fMRI","Reward Function","Affective Processing","Interoceptive Awareness","RECRUITING","2026-06-19",{"date":80,"type":34},"2026-06-23",{"date":82,"type":34},"2023-02-02",{"date":84,"type":21},"2027-12-31",{"name":40,"class":41},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":61,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100558563","screening-evaluation-and-assessment-sea-protocol-at-the-nida-irp-100558563","NCT06552741","Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP","Screening, Evaluation, and Assessment (SEA) Protocol at the NIDA IRP","* INCLUSION CRITERIA:\n\nThis protocol is seeking individuals with current or past SUDs and\u002For AUD, as well as those who have never had an SUD or AUD. These individuals also may or may not be in treatment for their AUD\u002FSUDs.\n\nTo be eligible to participate in this study, an individual must meet the following criteria:\n\n* Age 18-99 years old.\n* Proficient ability to read, write, and understand English.\n* Stated willingness to comply with all screening procedures and availability for the duration of the screening period\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nIndividuals who lack capacity to consent to research participation to this protocol as determined by the Evaluation to Sign Consent (ESC).","99 Years",{"count":95,"type":21},10000,"Background:\n\nPeople who will participate in research studies need to undergo proper screening, evaluation, and assessment (SEA). SEA helps keep those who participate in studies safe. It also helps ensure accurate study results. The National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) wants to screen people with alcohol and\u002For substance use disorders (ASUD) as well as people without ASUD for ongoing studies at NIDA in Baltimore, MD\n\nObjective:\n\nTo screen people with or without ASUD for ongoing studies at NIDA. The ultimate goals are to learn why some people (1) use drugs; (2) stop using drugs; (3) use drugs but do not get addicted; and (4) never use drugs snd to develop ASUD treatments.\n\nEligibility:\n\nPeople aged 18 years and older. They may (1) currently use nicotine, alcohol, opioids, cocaine, or other drugs; (2) no longer use them; or (3) have never used them.\n\nDesign:\n\nParticipants will have 1 screening visit that could last up to 8 hours. The visit may be split over more than 1 day. The duration of the screening may vary for each individual based on which studies they are interested in and screened for. The tests they undergo may vary and may include the following:\n\n* Physical exam.\n* Blood, saliva, and urine tests.\n* Breath samples that test for alcohol and carbon monoxide.\n* Test of heart function.\n* Smell test that measures sense of smell.\n* Tests of memory, attention, and thinking.\n* Mental health evaluation.\n* Mock magnetic resonance imaging (MRI) scan.\n* Questionnaires about alcohol and other drug use, mental health, medical history, and life in general.",[26,98],"Alcohol Use Disorder",[100,101,102,103,104,105,106,107,108],"Alcohol","Drug","Smoking","Substance","Opioid","Nicotine","Cocaine","CONTROL","Vaping","2026-06-02",{"date":111,"type":34},"2026-06-03",{"date":113,"type":34},"2024-09-04",{"date":115,"type":21},"2047-01-01",{"name":40,"class":41},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":65,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":144,"locationsCount":42},"100616716","employing-peer-outreach-and-whole-health-in-recovery-for-homeless-experienced-veterans-100616716","NCT07309224","Employing Peer Outreach and Whole Health in Recovery for Homeless-Experienced Veterans","Employing Peer Outreach and Whole Health in Recovery (EMPOWER) for Homeless-Experienced Veterans: A Hybrid Type III Implementation Trial (QUE 25-014)","EMPOWER","Inclusion Criteria:\n\n* Eligible patients will be identified from VA's Homeless Registry \"Hot Spot\" reports, which use real-time data on acute care service utilization to identify high-need, housing-insecure patients.\n* These reports identify Veterans on the VA Homeless Registry (i.e., those who had received VA housing services in the past two years) who had \\>1 hospital admissions and\u002For \\>2 ED visits in the past quarter of the fiscal year.\n* From these reports, the investigators will identify patients at each implementation site who are\n\n  * (a) currently enrolled in HUD-VASH\n  * (b) have a mental health and\u002For SUD diagnosis\n\nExclusion Criteria:\n\n* Not flagged on the VA's Homeless Registry Hot Spot Report\n* Not currently enrolled in HUD-VASH\n* Does not have a mental health and\u002For substance use disorder diagnosis\n* Is not a patient at a participating site of the implementation trial",{"count":126,"type":21},278,[67],"Homelessness is a national crisis in the United States, particularly in the veteran population. Due to multiple chronic conditions, homeless individuals frequently become hospitalized or are treated in emergency departments. Care engagement can mitigate this risk. Interventions grounded in evidence-based practices of peer support and whole health are effective for increasing care engagement. However, implementation of such interventions with high-acuity patients often requires strategies that are intensive and costly. This trial will evaluate the relative impacts and costs of using a high-intensity (vs. low-intensity) strategy to implement a peer-led, whole health intervention for homeless-experienced veterans in permanent supportive housing.",[26,130,131],"Mental Health Disorder","Homelessness",[133,134,135,136,137],"Veterans","Homeless Persons","Peer Influence","Whole Person Health","Implementation Science","2026-04-08",{"date":140,"type":34},"2026-04-09",{"date":48,"type":21},{"date":143,"type":21},"2030-09-30",{"name":145,"class":146},"VA Office of Research and Development","FED",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":42},"100627007","psychosocial-factors-in-dual-diagnosis-in-a-general-hospital-100627007","NCT07443033","Psychosocial Factors in Dual Diagnosis in a General Hospital","Psychosocial Protective Factors and Clinical-Functional Outcomes in Hospitalized Patients With Dual Diagnosis: An Observational, Cross-Sectional, Single-Center Study","DUAL-HVP","Inclusion Criteria:\n\n* Adults (≥18 years).\n* Hospitalized patients with a clinical diagnosis of dual diagnosis.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or acute clinical condition preventing assessment.\n* Refusal or inability to provide informed consent.",{"count":156,"type":21},125,"Dual diagnosis, defined as the co-occurrence of a mental disorder and a substance use disorder, is frequently associated with increased clinical severity, functional impairment, and poorer health outcomes. Identifying psychosocial protective factors related to better clinical and functional outcomes is essential to improve patient care and treatment planning.\n\nThe aim of this observational, cross-sectional, single-center study is to analyze psychosocial protective factors and their association with clinical-functional outcomes in hospitalized patients with dual diagnosis. The study will be conducted in a general hospital setting and will include adult inpatients diagnosed with dual diagnosis according to clinical criteria.\n\nSociodemographic, clinical, and psychosocial variables will be collected using standardized assessment tools and clinical records. The results of this study are expected to contribute to a better understanding of psychosocial factors associated with clinical severity and functional outcomes in patients with dual diagnosis, supporting more comprehensive and patient-centered care approaches.",[159,26,160],"Dual Diagnosis","Mental Disorders",[162,163,164,165,166,167,168,169,170,171],"Addiction psychiatry","Mental health","Cross-sectional study","Observational study","Hospitalized patients","Functional outcomes","Clinical outcomes","Protective factors","Psychosocial factors","Dual diagnosis","2026-02-24",{"date":174,"type":34},"2026-03-02",{"date":176,"type":21},"2026-03-01",{"date":178,"type":21},"2027-04-30",{"name":180,"class":181},"Hospital Virgen del Puerto","OTHER_GOV",{"id":183,"slug":4,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":61,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":65,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100626757","NCT07439783","Testing the CrOss Systems Technical Assistance for Retaining Staff (COSTARS) Model for Improving Staff Retention Among Child Welfare Workers and Peer Supporters, and Implementation of Evidence Based Interventions.","Staffing and Supports for Implementing Cross-System Interventions With Peer Mentors","COSTARS","Inclusion Criteria:\n\n* Adults employed as supervisors in child welfare agencies who are leading teams of case workers and family peer mentors as part of Ohio START implementation.\n\nExclusion Criteria:\n\n* Not involved in Ohio START",{"count":190,"type":21},200,[67],"The goal of this study is to test whether the CrOss System Technical Assistance for Retaining Staff (COSTARS) supervision leadership institute can promote workforce stability and improved implementation outcomes within the Ohio START child welfare program. The main questions it aims to answer are:\n\n* Among supervisors, caseworkers, and family peer mentors, what is the effect of COSTARS on staff retention and perceptions of the work environment?\n* What is the effect of COSTARS on service timeliness, implementation fidelity, and parent outcomes within Ohio START?\n\nResearchers will compare public children services agencies implementing COSTARS to those implementing supervision practices as usual to see if there are differences between groups in the outcomes described above.\n\nParticipating supervisors will:\n\n* Complete a 6-hour training workshop in the FOCUS model of supervision.\n* Participate in monthly group coaching sessions with other supervisors, for approximately one year.\n* Receive individualized feedback from coaches about their supervision performance.",[26,194,195,196,197],"Opioid Use Disorder","Child Maltreatment","Implementation","Peer Recovery Supporters","2026-02-23",{"date":200,"type":34},"2026-02-27",{"date":202,"type":21},"2026-03-30",{"date":204,"type":21},"2030-08-31",{"name":206,"class":207},"Alicia Bunger","OTHER",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":65,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":42},"100560692","personalized-approach-to-healthy-use-and-recovery-path-trial-100560692","NCT06580457","Personalized Approach to Healthy Use and Recovery (PATH) Trial","Understanding and Treating Substance Use Disorder and Comorbid Conditions in Veterans' Real-Life Settings","PATH","Inclusion Criteria:\n\n* Inclusion criteria for this study are intended to include most Veterans with SUD\n* inclusion criteria are current probable SUD as indicated by:\n\n  * a clinical score on the alcohol use disorders identification test (AUDIT) or drug use disorders identification test (DUDIT)\n  * past-month substance use\n  * a reliable access to a smartphone, tablet, or other device with capability of accessing and completing surveys throughout the day\n\n    * this will exclude those who are currently completing inpatient treatment\n\nExclusion Criteria:\n\n* exclusion criteria are being under the influence of a judgment-impairing substance at the time of consent (e.g., cannabis, alcohol, illicit opioids)\n\n  * participants will be invited to return another day\n* being legally compelled to complete treatment\n* or being under civil commitment\n\n  * due to lack of ability to give autonomous consent in these situations",{"count":217,"type":21},74,[67],"An important part of substance use treatment for many people is learning what triggers their substance use and urges, and how they can better manage those triggers. In this study, the investigators will generate a model for each individual that shows likely causal links between their substance use, urges, and comorbid symptoms (e.g., anxiety, depression, and PTSD), and the investigators will examine these models as a group to draw conclusions about common causes for substance use (and recovery) among Veterans with substance use disorders. The investigators will also test whether receiving a personal model and clinical feedback improves substance use disorder and comorbid symptom outcomes. Results will include both patient-reported and statistically-determined causes of substance use for individuals and groups, clinical impact of a personalized model and feedback session, and participant feedback about the relevance of this study and intervention.",[26],[222,223,224],"substance use disorder","precision medicine","ecological momentary assessment","2026-01-13",{"date":227,"type":34},"2026-01-15",{"date":229,"type":34},"2025-10-01",{"date":231,"type":21},"2030-03-29",{"name":145,"class":146},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":240,"minAge":17,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":65,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":42},"100605908","a-type-i-hybrid-effectiveness-implementation-trial-of-mio-100605908","NCT07168642","A Type I Hybrid Effectiveness-Implementation Trial of MIO","A Type I Hybrid Effectiveness-Implementation Trial of Mothering From the Inside Out (MIO)","Client Subjects\n\nInclusion Criteria:\n\n* Identifies as a woman\n* English-speaking\n* Age 18 years or older\n* Enrolled in outpatient substance use treatment for a substance use disorder (by DSMV criteria) at one of the four target clinics operated by participating agencies\n* Caring for at least one child between 0 and 60 months of age (either as guardian or working towards reunification with regular contact)\n\nExclusion Criteria:\n\n* Have severe mental health problems (e.g., actively suicidal, homicidal, psychosis)\n* Severely cognitively impaired\n* Have psychiatric or substance-related symptoms requiring inpatient hospitalization or ambulatory detoxification\n* Unable to speak English\n* Have a potential target child who has a severe medical condition that limits their ability to interact with their mother (such as paralysis or severe weakness)\n\nChildren Subjects\n\nInclusion Criteria:\n\n* Age 5 years or younger\n* Are in their biological mother's custody OR are in custody of family with the goal of reunification with their biological mother and have permission from the child's legal guardian to participate in this study\n\nExclusion Criteria:\n\n•In child welfare custody and goal is not reunification with biological mother\n\nCounselor Subjects\n\nInclusion Criteria:\n\n* Age 21 years or older\n* Employed as an addiction counselor at one of the participating agencies in one of the target clinics\n* Have a bachelor's degree or higher in psychology, social work, counseling, or a related field\n* Have secure administrative approval for a 1-hour per biweekly commitment to supervision and 2-3 hours weekly for MIO delivery\n* Do not intend to give notice and are not scheduled for medical or family leave during the study period\n* Willing to have counseling and supervision sessions recorded\n* Receive a mean score greater than 4 on the Clinical Reflective Functioning Scale\n* Are deemed capable to manage the responsibilities of being a counselor in a randomized trial (deliver MIO promptly to participants, compliant with study procedures and assessments, willing to receive supervision) by their supervisors\n\nExclusion Criteria:\n\n•None\n\nAgency Staff Subjects\n\nInclusion Criteria:\n\n* Employment at a participating agency for at least 3 months\n* Willingness to complete questionnaires and participate in a confidential interview or focus group\n* Fluency in English\n\nExclusion Criteria:\n\n•None","FEMALE",{"count":190,"type":21},[67],"Mothers with substance use disorders face unprecedented stress in their roles as parents working to care for their children while maintaining healthy recovery. Mothering from the Inside Out (MIO) is the first attachment-based parenting intervention designed specifically for mothers in recovery from substance use disorders that has been shown to have benefit for both mother and child in multiple randomized controlled trials. This project will: (a) test the effectiveness of MIO among women in outpatient treatment under 'real-world' conditions, (b) evaluate implementation in different settings, and (c) assess key implementation factors to support optimal uptake and treatment in future dissemination studies; closing an important science-to-service gap for an underserved population in an effort to support maternal and child health simultaneously.",[26],[222,246,247,248,249,250],"parenting","parenting intervention","Mothering from the Inside Out","MIO","SUD treatment","2026-01-06",{"date":253,"type":34},"2026-01-07",{"date":255,"type":34},"2025-12-18",{"date":257,"type":21},"2029-07-31",{"name":259,"class":207},"Baystate Medical Center",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":240,"minAge":17,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":65,"phases":268,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":42},"100609231","a-digital-intervention-to-decrease-self-stigma-among-pregnant-and-postpartum-women-with-substance-use-disorder-100609231","NCT07211867","A Digital Intervention to Decrease Self-Stigma Among Pregnant and Postpartum Women With Substance Use Disorder","Inclusion Criteria:\n\n* Pregnant women and new mothers (up to 12 months postpartum)\n* Adult (≥18 years of age)\n* Fluent in English\n* Currently owns or has ready (daily) access to a smartphone or tablet to use Enhearten.\n* Self-reports a history of substance use, excluding alcohol use, nicotine\u002Ftobacco use, and drugs taken as prescribed by a physician OR a history of substance use, excluding alcohol use, nicotine\u002Ftobacco use, and drugs taken as prescribed by a physician, is identified in chart review as documented by a healthcare provider\n\nExclusion Criteria:\n\n\\- Significant cognitive impairment that interferes with their ability to consent and complete study tasks as self-reported or documented in medical charts by a healthcare provider",{"count":267,"type":21},152,[67],"Digital interventions have the potential to support healthier behaviors among pregnant and postpartum women (PPW) with substance use disorders (SUDs) and may also provide a promising method for reducing their self-stigma. Enhearten is a digital intervention designed to foster adherence to medications for addiction treatment (MAT) while considering the unique needs of PPW, but its effects on self-stigma, treatment retention, and SUD outcomes have not been rigorously tested. The investigators will conduct an individual-level multicenter randomized controlled trial to test the feasibility, acceptability, and efficacy of Enhearten on reducing self-stigma and on improving SUD treatment and recovery outcomes with a stigma-focused ecological momentary intervention (EMI) designed to: 1) screen for feelings of stigma and 2) counteract these vulnerabilities among PPW with SUD via just-in-time interventions.",[26],[272,273,274,222],"pregnant and postpartum women","self-stigma","digital interventions","2025-11-25",{"date":277,"type":34},"2025-11-26",{"date":279,"type":34},"2025-11-24",{"date":281,"type":21},"2027-05",{"name":283,"class":207},"Washington University School of Medicine",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":65,"phases":293,"briefSummary":294,"conditions":295,"keywords":299,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":42},"100451254","osa-pap-treatment-for-veterans-with-sud-and-ptsd-on-residential-treatment-unit-100451254","NCT05156112","OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit","Examining Early Intervention Obstructive Sleep Apnea Treatment on Long-Term Outcomes in Veterans With SUD\u002FPTSD in a Residential Treatment Program","Inclusion Criteria:\n\n* a Veteran of the U.S. military or Reserve\u002FNational Guard member\n* at least 18 years of age\n* have an AHI 5 per hour\n* experienced trauma that occurred in childhood or adulthood; at least one month post-trauma\n* have current DSM-5 diagnoses of SUD via SCID-SUD module with a minimum 20 days of substance use in the last 90 days (Timeline Follow-back)\n* Full PTSD diagnosis via clinician administered PTSD scale\n* are literate in English\n* are on the PTSD track of the SARRTP unit\n* are capable of giving informed consent\n\nExclusion Criteria:\n\n* have central sleep apnea (AHI \\>=5 and \\> 50% central apneas)\n* arrives on the SARRTP unit already using a PAP device (Veteran's previously diagnosed with OSA, but not using PAP therapy will be eligible)\n* the SARRTP medical staff advises against the study based on medical history and physical examination; d) history of severe cognitive impairment (via MOCA \\\u003C 26)\n* history of psychosis or mania independent of substance use will be excluded because the presence of these disorders can impede therapy progress",{"count":292,"type":21},194,[67],"Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone. This is especially true in residential settings where both disorders are more severe than outpatient settings. Obstructive sleep apnea (OSA) is highly comorbid with both disorders and untreated OSA is associated with worse functional impairment across multiple domains, worse quality of life, worse PTSD, higher suicidal ideation, and higher substance use and relapse rates. Treating OSA with evidence-based positive airway pressure (PAP) in Veterans with SUD\u002FPTSD on a residential unit is a logical way to maximize treatment adherence and treatment outcomes. This study compares OSA treatment while on a SUD\u002FPTSD residential unit to a waitlist control group. The investigators hypothesize that treating OSA on the residential unit, compared to the waitlist control, will have better functional, SUD, and PTSD outcomes.",[296,297,26,298],"Post Traumatic Stress Disorder","Obstructive Sleep Apnea","Residential Treatment Program",[300,301,297,26,302,303],"Veteran","PTSD","PAP Treatment","Residential Treatment","2025-10-30",{"date":306,"type":34},"2025-11-03",{"date":308,"type":34},"2023-01-02",{"date":310,"type":21},"2027-05-31",{"name":145,"class":146},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":61,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":65,"phases":322,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":42},"100549359","smoking-cessation-cm-for-veterans-with-or-at-risk-for-cancer-100549359","NCT06432985","Smoking Cessation CM for Veterans With or at Risk for Cancer","Contingency Management for Veteran Smokers With or at Risk for Cancer","CM_TUD_Cancer","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Human Subjects Involvement and Characteristics: This Proof of Concept and Clinical Trial has three stages. The Proof-of-Concept Phase (Years 1-2) includes a Focus Group phase (Year 1) in which the investigators will recruit both Veterans and non-Veterans (VA clinical staff); and a Pilot Study (Year 2) in which the investigators will recruit Veterans in LCS or cancer treatment at San Francisco VA Healthcare System (SFVAHCS). If the Pilot Study is successful, the investigators will recruit Veterans in LCS or cancer treatment for the RCT (Years 3-6).\n* Focus Groups: For Focus Groups (Year 1), the investigators will recruit both Veterans and VA clinical staff at SFVAHCS.\n\nVeterans:\n\n* Age 18 years or older\n* Veteran eligible for VA healthcare\n* English-speaking\n* Received SFVAHCS cancer monitoring or treatment or LCS within the past 24 months\n* Active cigarette smoking within the past 24 months\n* Have access to Wi-Fi and a device that supports audio and video communication\n\nVA Clinical Staff:\n\n* Current member of clinical staff at the SFVAHCS\n* Have participated in the care of at least 5 VA cancer or LCS patients in the past 6 months\n\nPilot Feasibility Study (Year 2) and Randomized Controlled Trial\n\nInclusion criteria:\n\n* Age 18 years or older\n* Veteran currently receiving medical care at SFVAHCS (at least one clinical visit same calendar year for cancer)\n* English-speaking\n* Current, active (same calendar year) enrollment in VA LCS, or current (same calendar year) diagnosis of cancer documented in the VA medical record, confirmed through medical record review\n* Current (past 30 days) cigarette smoking a minimum of 1 cigarette per day (average), assessed by Timeline Followback (TLFB)92, 99-101\n* Open to receiving smoking cessation interventions\n\nExclusion Criteria:\n\nFocus Groups: For Focus Groups (Year 1), the investigators will recruit both Veterans and VA clinical staff at SFVAHCS.\n\nVeterans:\n\nExclusion criteria: Assessed by Co-PIs' medical record review:\n\n* Current severe, untreated mental illness (i.e., psychosis, bipolar disorder, and\u002For substance use disorder (SUD)) and\u002For\n* Current (past 30 days) active suicidal\u002Fhomicidal ideation or severe behavioral instability that would prevent participation\n* Never smokers or quit smoking for longer than 36 months prior to consent (4) no access to Wi-Fi or devices that support audio and video communication\n\nVA Clinical Staff:\n\nExclusion Criteria:\n\n* Unable to commit 1.5 hours (60 min focus group and self-report questionnaires)\n\nPilot Feasibility Study (Year 2) and Randomized Controlled Trial\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n* Evaluated by investigative team medical record review and clinical assessment:\n* Psychotic disorders, bipolar disorder, neurocognitive disorder, substance use disorders, or other psychiatric or medical conditions judged by the PI to be unstable in the past 30 days, based on screening results and\u002For medical record review, including conditions for which large sums of money would be potentially destabilizing\n* Untreated, current, active problem gambling, assessed by medical record diagnosis and\u002F or Problem Gambling Severity Index (PGSI) score 8\n* Metastatic cancer or enrollment in end of life\u002F palliative care\n* Unable to commit to time commitment required for participation\n* Currently pregnant or planning to become pregnant during the study (people of childbearing potential ages 18-55 who are pregnant or state that they plan to become pregnant during the study)\n* A suicide attempt or suicidal ideation with intent in the 30 days prior to enrollment\n* Concurrent enrollment in a tobacco cessation clinical trial",{"count":321,"type":21},108,[67],"Tobacco use among US Veterans poses significant health problems and challenges to their overall well-being. The aim of this project is to evaluate the effectiveness of a program called Contingency Management (CM) in helping Veterans quit smoking during lung cancer screening or cancer care at VA clinics. CM is a behavioral treatment that uses rewards to encourage smoking cessation when verified through biological testing. In the first year, the researchers will develop a mobile CM protocol based on feedback from Veterans and healthcare staff through focus groups. In the second year, they will conduct a pilot study to test the feasibility of the mobile CM program along with counseling and medication for 20 Veterans over a five-week period. The success of the pilot study will determine whether to proceed with a larger randomized controlled trial (RCT) in years three to six, comparing the efficacy of mobile CM with standard treatment. The project will take place at SFVA.",[325,26],"Tobacco Use Disorder",[327,328,329],"Tobacco","Contingency Management","Lung Cancer","2025-09-29",{"date":332,"type":34},"2025-09-30",{"date":334,"type":34},"2025-01-29",{"date":336,"type":21},"2031-09-30",{"name":145,"class":146},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":61,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":65,"phases":348,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":42},"100390638","successful-transitions-and-reintegration-tools-for-veterans-start-vets-100390638","NCT04366531","Successful Transitions and Reintegration Tools for Veterans (START-VETS)","Development of a Psycho-social Transition Program and Transition Assessment Tools for Veterans With Mental Illness and\u002For Substance Use Disorders Leaving Prison","START-VET","Inclusion Criteria:\n\n* Veteran with mental illness and\u002For substance use disorder released from prison within the past 36 months\n\nExclusion Criteria:\n\n* psychosis or cognitive impairment precluding active participation",{"count":347,"type":21},20,[67],"This study will develop prison reentry materials for Veterans leaving prison.",[26,351,352],"Mental Illness","Recently Incarcerated",[354,355,356,222],"reentry","Mental illness","prison","2025-09-22",{"date":359,"type":34},"2025-09-26",{"date":361,"type":34},"2020-08-03",{"date":363,"type":21},"2026-12-31",{"name":145,"class":146}]